Gilder Gagnon Howe & Co. LLC cut its stake in shares of Senestech, Inc. (NASDAQ:SNES) by 0.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,047,169 shares of the company’s stock after selling 2,621 shares during the period. Gilder Gagnon Howe & Co. LLC owned about 10.25% of Senestech worth $5,969,000 at the end of the most recent quarter.
Senestech, Inc. (NASDAQ SNES) traded down 8.63% during trading on Friday, hitting $2.54. The stock had a trading volume of 340,960 shares. Senestech, Inc. has a 12-month low of $2.03 and a 12-month high of $10.69. The company’s market cap is $26.23 million. The company has a 50 day moving average of $3.87 and a 200-day moving average of $6.55.
Senestech (NASDAQ:SNES) last issued its earnings results on Thursday, August 10th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by $0.07. The business had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.10 million. On average, equities analysts predict that Senestech, Inc. will post ($1.30) EPS for the current year.
COPYRIGHT VIOLATION NOTICE: This report was originally published by BNB Daily and is the sole property of of BNB Daily. If you are reading this report on another website, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The legal version of this report can be read at https://www.baseball-news-blog.com/2017/08/19/gilder-gagnon-howe-co-llc-lowers-stake-in-senestech-inc-snes-updated.html.
SNES has been the topic of several research analyst reports. Roth Capital set a $14.00 price objective on Senestech and gave the company a “buy” rating in a research note on Saturday, May 13th. Zacks Investment Research lowered Senestech from a “hold” rating to a “sell” rating in a research note on Thursday, June 1st.
In other news, COO Andrew Altman bought 20,000 shares of the stock in a transaction on Friday, August 18th. The shares were purchased at an average price of $2.77 per share, for a total transaction of $55,400.00. Following the completion of the purchase, the chief operating officer now directly owns 2,600 shares of the company’s stock, valued at approximately $7,202. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, CFO Thomas C. Chesterman sold 10,000 shares of the business’s stock in a transaction dated Monday, June 12th. The shares were sold at an average price of $5.71, for a total value of $57,100.00. Following the completion of the transaction, the chief financial officer now owns 16,287 shares in the company, valued at approximately $92,998.77. The disclosure for this sale can be found here. Insiders acquired 54,100 shares of company stock worth $155,730 in the last 90 days. Corporate insiders own 27.40% of the company’s stock.
SenesTech, Inc is a United States-based biotechnology platform and research company. The Company is engaged in developing a technology for managing animal populations by fertility control. It offers ContraPest, a fertility control product candidate. ContraPest’s technology and approach targets the reproductive capabilities of both sexes.
Receive News & Ratings for Senestech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senestech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.